June is Myasthenia Gravis Awareness Month

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Two different approaches in the treatment of gMG: an overview of zilucoplanand rozanolixizumabclinical trial programs

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Wednesday, August 11, 2021
Sponsor Information: 

This Industry Update Webinar is sponsored by UCB. This program is not sponsored, endorsed, or accredited by MDA.


Dr. Tuan Vu
Division Director, Neuromuscular Medicine & EMG
USF Health
Activity Overview: 

This Industry Update Webinar for clinicians is presented by UCB, featuring information for clinicians on gMG. On August 11, 2021 at 2:00pm EST in a 30-minute webinar, UCB presented "Two different approaches in the treatment of gMG: an overview of zilucoplan and rozanolixizumab clinical trial programs." This webinar discussed how the rigorous understanding of the mechanistic and clinical benefit of inhibition of FcRn and complement has led to several late-stage trials that specifically target these mechanisms in patients with gMG. This webinar covered the pathophysiology of gMG, the current standard of care, as well as provided an overview of UCB’s respective clinical programs in gMG with rozanolixizumab and zilucoplan.